Levebon

Levetiracetam, the active ingredient in Levebon, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levebon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is used to control various seizure types in epilepsy. - Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes. - Myoclonic seizures: decreases sudden muscle jerks associated with epilepsy.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or lacking energy. - Headache: mild to moderate head pain. - Irritability: increased mood swings or agitation. - Nausea: feeling of stomach upset. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: depression, suicidal thoughts, or severe anxiety. - Blood disorders: low white blood cells or platelets. - Liver dysfunction: elevated liver enzymes or jaundice. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions. - Renal function: dose may need adjustment in impaired kidney function. - Hepatic function: monitor liver enzymes in patients with liver disease. - Psychiatric history: observe for mood changes or suicidal ideation. - Concomitant CNS depressants: may increase sedation. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with several medications; awareness of interaction severity is essential.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease levetiracetam effectiveness.

Moderate Interactions (Monitor Closely): - Alcohol: can enhance central nervous system depression. - Sedative antihistamines: may increase drowsiness. - Other antiepileptic drugs: monitor seizure control and side‑effect profile. - Oral contraceptives: potential reduction in contraceptive efficacy. - Immunosuppressants: observe for altered drug levels.